Bessemer Group’s TherapeuticsMD TXMD Stock Holding History

Bessemer Group’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-8	Closed	-$2K	–	1912
2016 Q4	$2K	Buy	+8	New	+$2.48K	﹤0.01%	1865

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Bessemer Group's TXMD Position: Q1 2017 in Review

Bessemer Group sold out of TherapeuticsMD (TXMD) in Q1 2017, closing a stake of 8 shares — an estimated $2K sold.

Bessemer Group first reported a position in TXMD in Q4 2016 and held it in 1 quarter. The position peaked at $2K in Q4 2016. 138 funds tracked by Wall St. Rank hold TXMD as of Q1 2017.

Bessemer Group reported no remaining TherapeuticsMD position as of Q1 2017 after selling out during the quarter.
Bessemer Group sold 8 TherapeuticsMD shares in Q1 2017, an estimated $2K.
Bessemer Group first reported a position in TherapeuticsMD in Q4 2016 and held it in 1 quarter.
Bessemer Group's TherapeuticsMD position peaked at $2K in Q4 2016.
138 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2017.

Based on Bessemer Group's 13F filing for Q1 2017, filed 12 May 2017.